With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Oprah Winfrey is sparking a debate around weight, willpower and perception after the media mogul revealed her perceptions ...

Underrepresentation of women as participants and researchers in CV clinical trials remains a problem, asserts a review ...

The risks of 'miracle' weight loss jabs such as Ozempic, Wegovy and Mounjaro have been laid bare by a landmark study ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Indeed, it's often described as a "wonder drug." That hasn’t stopped a torrent of fat phobia and often frankly hateful ...

Ro explores the relationship between fiber and weight loss, six high-fiber foods for weight loss, and how incorporating these ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to US Food and Drug Administration approval.